Best Work Places

February 09, 2026 | Best Work Places

WuXi Biologics Honoured with EcoVadis Platinum for ESG Excellence

WuXi Biologics, announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the third year the company has received the rating's highest level of recognition. EcoVadis is among the world's most trusted and comprehensive sustainability assessment platforms, evaluating companies' ESG performance through 21 criteria across four key areas — Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. WuXi Biologics was ranked in the top 1% of more than 150,000 companies evaluated worldwide. Being awarded the Platinum Medal reflects company's robust policies, rigorous implementation mechanisms, and proven performance outcomes across all ESG dimensions, validated by external stakeholders and third-party professionals. WuXi Biologics continues to strengthen its sustainability performance across the EcoVadis assessment areas. Examples of recent initiatives include: SBTi-Approved Targets: The company's near-term and net-zero GHG emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), making WuXi Biologics one of the first in the industry to receive approval for both near-term and net-zero targets. Green CRDMO White Paper: The White Paper — launched to accelerate sustainability in the biologics industry — details WuXi Biologics' green innovation technologies across research, development and manufacturing, and showcases the significant carbon reduction achieved through green operations. It also compiles 242 energy-saving cases across five key energy-saving scenarios, 12 typical energy systems, and 25 technology categories. ISO 20400 Certification: The company has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles and procurement practices, while promoting transparency and responsibility across the supply chain. Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very pleased to be recognized once again by EcoVadis with the Platinum Medal, which highlights our success in advancing our sustainability capabilities. As a global leader in Green CRDMO, we are committed to continuously delivering ESG excellence, enabling partners worldwide to fulfill ESG goals, and jointly working with all stakeholders to promote responsible practices throughout the entire value chain." A Long-Term Commitment to Sustainable Value Creation Achieving the EcoVadis Platinum Medal for the third consecutive year, WuXi Biologics further reinforces global clients' confidence in its reliability, responsibility, and forward-thinking vision, with unwavering adherence to rigorous sustainability, quality, and compliance standards for long-term collaborations in the evolving global ESG landscape.

February 06, 2026 | Best Work Places

J&J Recognized by HBA for Global Impact in Healthcare Leadership

Johnson & Johnson has been named the inaugural recipient of the Global Impact Award by the Healthcare Businesswomen's Association (HBA), a global leadership accelerator, business growth partner, and enterprise solution for the healthcare and life sciences industries. The HBA's first-ever Global Impact Award recognizes organizations whose leadership practices, innovation strategies, collaboration models, and business performance work together to drive meaningful, sustained change across healthcare and life sciences. The award takes an enterprise-wide view, celebrating how companies develop leaders, advance innovation, build partnerships, and align purpose with performance to deliver impact at scale for patients, the workforce, and healthcare systems worldwide. "Healthcare is inherently global, and leadership must be as well," said Mary Stutts, Chief Executive Officer of the HBA. "This inaugural award recognizes organizations that embed purpose into how they lead, innovate, and operate at scale. Johnson & Johnson demonstrates what it looks like to translate values into measurable impact across markets, communities, and healthcare systems worldwide." Johnson & Johnson will be celebrated during the HBA's Global Ascension Leadership Experience on 23-24 April 2026, in San Diego, California. Designed for leaders navigating an increasingly complex healthcare landscape, this two-day leadership experience convenes influential voices across biotech, biopharma, medtech, digital health, research, healthcare, and the broader life sciences ecosystem for future-focused learning, intentional connection, and leadership insight. Registration for the Global Ascension Leadership Experience is now open. Inaugural Global Impact Award Winner: Johnson & Johnson Johnson & Johnson was named the inaugural recipient of the HBA Global Impact Award for translating values-driven leadership into measurable impact for patients, the healthcare workforce, and health systems around the world. Guided by the company's Credo values, Johnson & Johnson embeds purpose across leadership and talent development, innovation, and social impact—aligning decisions globally around long-term commitments to patients, employees, communities, and shareholders. A cornerstone of this impact is the company's focus on building future-ready leaders. Through its partnership with the HBA, Johnson & Johnson has expanded leadership development, mentorship, and global visibility for emerging talent, co-creating curricula, launching mentorship cohorts, driving advocacy, and strengthening leadership pipelines across regions through initiatives like the HBA Global Ambassador program. Johnson & Johnson's commitment to innovation and business performance further distinguishes the organization. In 2025, the company developed the strongest portfolio and pipeline in its history, taking significant steps to transform lives in six key areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. Globally, J&J is closing the gap between communities and care through J&J CareCommunity. Building on a long legacy of impact, its new social impact platform is rooted in championing nurses and health workers, the heart of the care system, and advancing programs that improve access to quality care for communities worldwide. "We are deeply honored to receive the HBA Global Impact Award, which reflects the dedication and passion of our Johnson & Johnson teams worldwide," said Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs, Johnson & Johnson. "This recognition affirms our ongoing commitment to developing leaders, nurturing innovation, and advancing partnerships that drive meaningful change for patients, our workforce, and healthcare systems everywhere."

February 05, 2026 | Best Work Places

KLAS Names CodaMetrix No. 1 in Autonomous Medical Coding

CodaMetrix, the market leader in autonomous medical coding, announced it has been ranked No. 1 in the 2026 Best in KLAS segment for Autonomous Coding, reflecting its leadership in defining and setting the performance standard for the category. "The Best in KLAS winners have earned the trust of their customers over the past year," said Adam Gale, CEO of KLAS Research. "With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come." Health systems today face tighter budgets, workforce shortages, and growing patient volumes, while navigating shifting payer guidelines. Medical coding remains a cornerstone of reimbursement, yet complex cases and persistent staffing shortages continue to create operational and financial bottlenecks. While many solutions offer partial automation or AI-assisted workflows, true autonomy has remained elusive. CodaMetrix addresses this gap, enabling health systems to: Automatically code high-volume cases end to end, without routine human intervention Maintain enterprise-grade accuracy and auditability Scale consistently across specialties and facilities Deliver measurable operational and financial outcomes Unlike solutions focused on narrow use cases, CodaMetrix's CMX CARE™ platform has demonstrated enterprise-wide adoption, with diverse specialty representation reflected in KLAS customer interviews—including Radiology, Pathology, Surgery, and Evaluation & Management—as reported in the 2025 KLAS Autonomous Coding report. In that report, customer feedback reflects performance across key dimensions such as likelihood to recommend, integration support, implementation quality, and measurable outcomes—highlighting strong buyer confidence: 93% of customers would buy again 93% say CodaMetrix is part of their long-term plan 8.0 "Likely to Recommend" score "We've spent years building AI that understands the full clinical story behind every code, not just replicating errors that impact health systems' bottom lines," said Hamid Tabatabaie, CEO of CodaMetrix. "Health systems don't just need automation, they need a partner that raises the bar on accuracy, consistency, and coding quality compliance across the enterprise. That's the role CodaMetrix plays every day."

January 30, 2026 | Best Work Places

Xevant Named a 2025 Modern Healthcare Best in Business Company for AI

Xevant, a leader in real-time pharmacy benefits intelligence, announced it has been named a 2025 Modern Healthcare Best in Business company in the Artificial Intelligence (AI) category. The recognition honors healthcare suppliers and technology partners whose innovations delivered measurable impact across the healthcare ecosystem in 2025. Xevant was recognized for applying AI to help employers, health plans, and pharmacy benefit stakeholders identify and act on opportunities to achieve the lowest net pharmacy cost—moving beyond retrospective reporting to real-time, operational decision-making. Xevant is honored to be recognized by Modern Healthcare for this work. At the core of this approach is VerX, Xevant's AI-driven orchestration platform, which analyzes complex pharmacy data to surface inefficiencies, prioritize actions, and guide decisions across PBM contracts, formularies, pharmacy channels, and specialty drug spend. By enabling timely intervention—not just insight—Xevant helps organizations manage pharmacy cost drivers with greater accountability and less disruption. "Artificial intelligence only matters if it drives better decisions that lead to optimal performance," said Brandon Newman, CEO of Xevant. "This recognition validates our focus on using AI to turn pharmacy data into action—helping organizations actively manage cost and complexity in real time, not months after the fact." The Modern Healthcare Best in Business Awards, announced in January 2026, recognize innovative healthcare suppliers, vendors, and partners for advancing efficiency and excellence across areas including data analytics, artificial intelligence, and patient engagement.

January 29, 2026 | Best Work Places

Samsung Biologics Recognized Among World’s Most Sustainable Companies

Samsung Biologics , a leading contract development and manufacturing organization (CDMO), announced that it has received the EcoVadis' Platinum Sustainability Rating, the highest level of recognition for corporate sustainability performance. The Platinum rating places Samsung Biologics in the top one percent of companies evaluated globally by EcoVadis, a leading sustainability assessment platform that measures corporate social responsibility performance across four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The EcoVadis rating is widely referenced by multinational organizations, including global pharmaceutical companies, as a key benchmark for supply chain sustainability and partnership evaluation. EcoVadis recognized Samsung Biologics for the continued strengthening of its sustainability management systems and execution, reflecting progress across these assessment categories throughout its operations and supply chain. Samsung Biologics previously received the Gold Sustainability Rating in 2024, underscoring a sustained trajectory of improvement. "This recognition reflects the steady progress we have made in advancing sustainability practices across our operations and supply chain," said John Rim, President and CEO of Samsung Biologics. "As ESG expectations continue to evolve globally, we remain focused on our commitment to responsible business practices that support long-term partnerships and contribute to a more sustainable healthcare ecosystem." Samsung Biologics has continued to enhance its sustainability initiatives in recent years, including expanding the use of renewable energy across operations and reinforcing ethical and compliance frameworks. The company received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP) in December 2025. As a Champion of the Sustainable Markets Initiative Health Systems Task Force, Samsung Biologics also continues to engage global suppliers in decarbonization efforts and the development of more resilient value chains.

January 23, 2026 | Best Work Places

Hansa Biopharma Honored with 2025 SwedenBIO Award

Hansa Biopharma AB announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was presented at the SwedenBIO Summit in Stockholm, where Hansa was selected as the winner among the many nominated companies. Since its inception in 2007, the SwedenBIO Award has celebrated companies that drive meaningful scientific progress, operational excellence, and international impact. This year's motivation highlights Hansa Biopharma for transforming Swedish scientific excellence into global medical impact and serving as a bold guiding star in building commercial capabilities for global markets. Through its pioneering enzyme technology, Hansa enables life-saving transplantation for highly sensitized patients with previously unmet needs. By advancing breakthrough innovation and delivering strong clinical results, the company strengthens Sweden's position as a leader in life science innovation. Renée Aguiar-Lucander, CEO, Hansa Biopharma said, "I am truly delighted and deeply honored to receive this award on behalf of everyone at Hansa Biopharma. This recognition reflects the great momentum we've built heading into 2026—powered by our strong U.S. Phase 3 data, the upcoming FDA review process, and the anticipated Phase 3 readout from our European Phase 3 trial later this year. Thank you to the SwedenBIO organization and judges for this recognition. We're proud of how far we've come, and excited for the journey ahead

January 22, 2026 | Best Work Places

Quest Diagnostics Recognized for Healthcare Leadership on Fortune® 2026 Most Admired List

Quest Diagnostics, a leading provider of diagnostic information services, announced that it has been named to the Fortune® magazine 2026 World's Most Admired Companies™ list, for the 12th consecutive year. "Quest's recognition as one of the world's most admired companies reflects the commitment of our 55,000 colleagues to living our purpose every day: working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "We are proud to again be named among this elite list of globally respected companies and even more proud to continue our important work at the center of healthcare, delivering diagnostic insights that illuminate a path to better health." In addition to the overall ranking, Quest ranked number two in the "Health Care: Pharmacy and Other Services" industry category. Fortune's World's Most Admired recognition is based on nine key attributes related to corporate reputation, including quality of products and services, innovation, long-term value and financial profile, social, environmental and community responsibility, and people management. Consulting firm Korn Ferry collaborated with Fortune to survey thousands of executives, directors and analysts who rated companies in their industry, analyzing nearly 700 companies. A company's score must rank in the top half of its industry survey to be listed as a World's Most Admired Company.

January 21, 2026 | Best Work Places

CHCP Honored as National Top Workplace and Top Education Institution

The College of Health Care Professions (CHCP) was named a National Top Workplace by Top Workplaces USA for the fourth consecutive year. In addition to the national honor, every CHCP campus was individually recognized as a Top Workplace, demonstrating the strength and consistency of CHCP's culture across the entire institution. Based entirely on employee feedback, these awards celebrate organizations that excel in workplace culture, employee appreciation, professional development, and leadership. This year, CHCP was further distinguished with the inaugural national Education Award, recognizing top-performing colleges and universities. In addition to the workplace recognitions, two CHCP faculty members were separately honored nationally for outstanding contributions to allied health education by the Accrediting Bureau of Health Education Schools (ABHES) : Krystal Dispennette, alumna and instructor at CHCP's San Antonio campus, was named the 2025 Master Teacher of the Year by ABHES and Elsevier. The award recognizes innovation, excellence in teaching, and measurable impact on student success. Dispennette's journey—from a teenage mom to nationally recognized educator—exemplifies the power of stackable healthcare training pathways and holistic student support. Ceferino Ibarra III, M.Ed., CPTEd, was honored nationally as a 2025 Exceptional Educator by CECU, Career Education Colleges and Universities. His innovation and dedication to adult learners have made a lasting impact on students and the wider community, demonstrating the excellence CHCP faculty bring to every classroom. The honors come as the United States faces a critical shortage of allied health care workers, with more than eight in ten healthcare facilities experiencing allied healthcare professional shortages. Creating a workplace where employees feel supported, valued, and empowered is a critical piece of helping institutions like CHCP continue to deliver high-quality education that meets the nation's healthcare and employer needs. "Creating an environment in which employees can grow and succeed is the foundation of supporting our learners," said Irma Arguijo-Rivera, PHR, Chief People Officer at CHCP. "These awards reflect CHCP's commitment to investing in our team members' growth, personally and professionally, while fostering a culture of innovation, collaboration, and excellence." Adding to its honors this year, CHCP's McAllen campus was named 2025 School of the Year by Career Colleges & Schools of Texas (CCST). Celebrating its 10th anniversary, the McAllen campus has graduated more than 3,000 students. The campus was recognized for its exemplary student outcomes, community service, and contribution to workforce development. Under the leadership of Campus President Andrea Hernandez, CHCP McAllen has become a model of community engagement, from hosting health fairs and providing free screenings to volunteering at local food banks and maintaining a city park adopted by the school. Eric Bing, Chancellor and CEO of CHCP, added, "Winning Top Workplaces for the fourth consecutive year—alongside our McAllen campus's recognition as School of the Year and our faculty's national honors—shows that when we prioritize our employees and educators, we directly strengthen the student experience. Our faculty and staff are at the heart of every learner's success, and their dedication is building the healthcare workforce our country urgently needs."

January 16, 2026 | Best Work Places

Amplifon Only Hearing Care Firm Named Global Top Employer 2026

Amplifon, the global leader in hearing care services and solutions, is one of 17 companies worldwide certified as a Global Top Employer in 2026, as well as the only company in the hearing care sector to obtain this international recognition for good practices in human resources management and the workplace. "This important recognition – comments Enrico Vita, Amplifon CEO – rewards our company's continuous commitment to people development, our consistency with our values, and our ability to translate them into our mission every day: improving the quality of life of our customers. The Top Employer certification represents a significant milestone in a long-term journey and, at the same time, an incentive for us to continue striving to do even better". "We are extremely proud to be the first Italian company to achieve this important recognition on a global scale – says Giovanni Buonajuto, Chief HR Officer at Amplifon – which makes us a global benchmark in attracting and developing talent. This certification is testament to our ongoing commitment to the development and growth of our employees and to an organizational environment characterized by a strong human dimension that encourages the exchange and generation of ideas." The Amplifon group currently employs over 20,000 people in 26 countries and five continents, representing over 100 different nationalities. The average age of the group's employees and collaborators is under 40, and more than 70% of the company's workforce is women. Each year, the company provides each of its employees with an average of at least three days of training. Top Employer is the official recognition of corporate excellence in policies and strategies in HR development and workplace improvement. The program, created by the Top Employers Institute, the global organization that identifies excellence in human resources management, ranked and certified more than 2,400 companies in 125 countries in 2025. Only the companies that meet the highest standards in six macro areas (people strategy, work environment, talent acquisition, training, diversity and inclusion, well-being) can access certification.

January 13, 2026 | Best Work Places

Deepson Bio Secures Highest Honor at 2025 Korea Invention Patent Exhibition

Deepson Bio Co., Ltd., a medical technology company focused on ultrasound-based approaches to dementia treatment, was honored with the Presidential Award, the highest recognition presented at the event, at the 2025 Korea Invention Patent Exhibition held at COEX in Seoul in December 2025. The Korea Invention Patent Exhibition is South Korea's largest intellectual property awards program, hosted by the Ministry of Intellectual Property and organized annually by the Korea Invention Promotion Association to identify and recognize notable domestic technologies and patented innovations, with the goal of supporting their translation into commercial applications. While approximately 100 institutions receive honors including the Presidential Award, the Prime Minister's Award, and the Minister of Science and ICT Award, the Presidential Award represents the highest level of distinction and is granted to only one organization each year. The winning products selected for this event were showcased at COEX in Seoul during the exhibition period in December 2025. Deepson Bio received the Presidential Award for its "Ultrasound devices for promoting waste product emissions in the brain lymphatic system using interactive ultrasound irradiation by multiple transducers" (Patent No. 10-2317379), which has been under research and development since 2018 and was registered in 2021; the underlying principle of the technology involves the application of low-frequency ultrasound to support the clearance of metabolic waste in the brain, including beta-amyloid, which has been linked in the scientific literature to dementia-related pathology. As a non-invasive and non-pharmacological approach, the ultrasound-based method is designed to avoid certain risks associated with existing treatment modalities, such as blood-brain barrier disruption, allergic reactions, and cerebral hemorrhage, and may offer broader applicability across multiple neurodegenerative conditions, including normal pressure hydrocephalus. Deepson Bio has developed its proprietary investigational medical device, "Neuclare," for the treatment of dementia based on this technology, and following the completion of exploratory clinical trials, the company plans to obtain approval for pivotal clinical trials from the Ministry of Food and Drug Safety; it further aims to conduct clinical trials at seven leading hospitals, including Seoul National University Bundang Hospital, Hallym University Dongtan Sacred Heart Hospital, Ewha Womans University Mokdong Hospital, Ewha Womans University Seoul Hospital, Soonchunhyang University Cheonan Hospital, Inha University Hospital, and The Catholic University of Korea St. Vincent's Hospital. "This Presidential Award recognizes the scientific and technological potential of ultrasound-based devices as a future therapeutic option in the field of dementia care," said Donghyuk Lee, CEO of Deepson Bio. "As we move forward with the next phase of clinical development for Neuclare, our focus will remain on generating robust clinical evidence while preparing for commercialization, including long-term plans to enter international markets such as the United States and Japan, subject to regulatory approval."

Page 1 of 9

Featured Recruiters